Genentech, a subsidiary of Roche, has recently undergone layoffs, affecting several vice presidents, including Vishva Dixit, Man-Wah Tan, and Todd McDevitt, as part of a restructuring within its Research and Early Development (gRED) group. The company is shutting down its physiological chemistry and infectious disease teams, although it did not disclose the total number of positions eliminated. Despite these job cuts, Genentech is still hiring for critical roles within gRED to align with its core therapeutic areas. This is not the first round of layoffs at Genentech; past reductions have impacted hundreds of employees as part of broader organizational changes. The company emphasizes the need to adapt to a fast-paced industry to continue delivering effective healthcare solutions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fiercebiotech.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed
